Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute (NCI)
Tianjin Medical University Cancer Institute and Hospital
Intergroupe Francophone de Cancerologie Thoracique
Peking University Cancer Hospital & Institute
Yale University
Dizal Pharmaceuticals
Anhui Provincial Cancer Hospital
Centre Francois Baclesse
Maastricht University Medical Center
Fundación GECP
Hunan Province Tumor Hospital
Sun Yat-sen University
Sun Yat-sen University
University of Rochester
Hunan Province Tumor Hospital
Sun Yat-sen University
Columbia University
Second Affiliated Hospital of Guangzhou Medical University
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
Hoffmann-La Roche
Xinqiao Hospital of Chongqing
Hunan Province Tumor Hospital
The First Affiliated Hospital of Xinxiang Medical College
Duke University
Sun Yat-sen University
Eastern Cooperative Oncology Group
Qingdao Central Hospital
Intergroupe Francophone de Cancerologie Thoracique
The Second Affiliated Hospital of Shandong First Medical University
Big Ten Cancer Research Consortium
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Fujian Cancer Hospital
Genentech, Inc.
Rutgers, The State University of New Jersey
ETOP IBCSG Partners Foundation
Case Comprehensive Cancer Center
Fox Chase Cancer Center
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Shanghai Chest Hospital
Eli Lilly and Company
Barbara Ann Karmanos Cancer Institute
Sichuan Cancer Hospital and Research Institute
Amgen
Dutch Society of Physicians for Pulmonology and Tuberculosis
Second Affiliated Hospital of Nanchang University